Skip to main content
. 2020 Jul;9(7):4111–4120. doi: 10.21037/tcr-20-1451

Figure 4.

Figure 4

Kaplan-Meier analysis of OS and PFS for hepatic carcinoma patients. OS curve (A), PFS curve (B). OS, overall survival; PFS, progression-free survival; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.